Catalent Expands UpTempo AAV Platform To Accelerate Development Of Gene Therapies
March 09, 2023
March 09, 2023
SOMERSET, New Jersey, March 9 -- Catalent Inc., a pharma, biotech and consumer health company, issued the following news on March 9, 2023:
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The platform now includes an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to sup . . .
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The platform now includes an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to sup . . .